LEP and hypoalphalipoproteinemia, primary, 1: Similar to the anti-resorptives, few studies have examined the impact of osteoanabolic drugs [such as teriparatide, recombinant PTH (rPTH), abaloparatide, romosozumab, recombinant leptin (metreleptin), rhIGF-1, and DHEA] on bone outcomes in FHA.